HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States
- DOI
- 10.1016/j.rpth.2025.103098
- Published
- 2025-11
- Container
- Research and Practice in Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.rpth.2025.103098,
title = {HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States},
author = {Mark T. Reding and Beng Fuh and Vanessa Salinas and Maissaa Janbain},
year = {2025},
journal = {Research and Practice in Thrombosis and Haemostasis},
doi = {10.1016/j.rpth.2025.103098},
url = {https://doi.org/10.1016/j.rpth.2025.103098}
}RIS
TY - JOUR TI - HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States AU - Mark T. Reding AU - Beng Fuh AU - Vanessa Salinas AU - Maissaa Janbain PY - 2025 JO - Research and Practice in Thrombosis and Haemostasis DO - 10.1016/j.rpth.2025.103098 UR - https://doi.org/10.1016/j.rpth.2025.103098 ER -
APA
Reding, M. T., Fuh, B., Salinas, V., & Janbain, M. (2025). HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2025.103098
Source records
- crossref · retrieved 2026-09-26T04:23:15.351Z